In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Editorial Advisory Board
Ask The Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Guidelines for Contributors
Report Store
UsernamePublicRestriction
Tags:
BioPharmaceutical Strategy Clinical Trials

Promoting Me-Too Biologicals: Portfolio vs. Single Product Approach

Executive Summary

Novo Nordisk's grand plan for pitting its new basal insulin Levemir against Aventis' dominant Lantus is to promote the product in the context of the company's broader insulin portfolio. Novo believes its portfolio approach should capture a greater overall share of the insulin space than Aventis with its one-size-fits-all strategy.
Table

View full table

Advertisement

Related Content

In Vivo
Antegren: Shaking Up the MS Market?
In Vivo
Antegren: Shaking Up the MS Market?
In Vivo
Aventis: Building on a Base in Diabetes

Topics

Related Companies

Advertisement
Tags:
BioPharmaceutical Strategy Clinical Trials
UsernamePublicRestriction

Register

IV002410

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By